WO2009038659A3 - Nanoparticules de silice organiquement modifiées avec des photosensibilisateurs incorporés par covalence pour l'administration de médicaments lors d'une thérapie photodynamique - Google Patents
Nanoparticules de silice organiquement modifiées avec des photosensibilisateurs incorporés par covalence pour l'administration de médicaments lors d'une thérapie photodynamique Download PDFInfo
- Publication number
- WO2009038659A3 WO2009038659A3 PCT/US2008/010608 US2008010608W WO2009038659A3 WO 2009038659 A3 WO2009038659 A3 WO 2009038659A3 US 2008010608 W US2008010608 W US 2008010608W WO 2009038659 A3 WO2009038659 A3 WO 2009038659A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photosensitizers
- nanoparticles
- imaging agents
- covalently linked
- photosensitizer
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 6
- 239000003504 photosensitizing agent Substances 0.000 title abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title abstract 3
- 238000012377 drug delivery Methods 0.000 title 1
- 238000002428 photodynamic therapy Methods 0.000 title 1
- 239000012216 imaging agent Substances 0.000 abstract 4
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000004036 bacteriochlorins Chemical class 0.000 abstract 1
- -1 benzochlorins Chemical class 0.000 abstract 1
- 150000004035 chlorins Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des nanoparticules contenant des photosensibilisateurs liés par covalence qui remédient au problème de la libération prématurée et améliorent donc le résultat de la PDT. L'invention concerne des nanoparticules à base de silice qui contiennent au moins un photosensibilisateur lié par covalence. Le photosensibilisateur est de préférence constitué de composés à base de tétrapyrrole de types porphyrines, chlorines, bactériochlorines, benzochlorines, dérivés de benzoporphyrine, phéophorbides, notamment pyrophéophorbides, et phthalocyanines, naphthanocyanines avec et sans systèmes de cycles condensés et dérivés de tous les composés ci-dessus. La nanoparticule peut également comprendre des agents d'imagerie liés par covalence, par exemple radionucléides, agents d'imagerie par résonance magnétique (RM) et fluorescence. Les agents d'imagerie et les photosensibilisateurs peuvent se trouver à la périphérie (surface) des nanoparticules pour augmenter leur efficacité. Des nanoparticules spécifiques d'une cible peuvent être obtenues en incorporant des molécules de ciblage biologique, comme des anticorps spécifiques sur la surface, qui réagissent avec des ligands particuliers pour obtenir une spécificité de cible. Des agents de diagnostic peuvent être présents dans l'anticorps en plus d'agents d'imagerie et de photosensibilisateurs spécifiques d'une tumeur.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99380707P | 2007-09-14 | 2007-09-14 | |
US60/993,807 | 2007-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009038659A2 WO2009038659A2 (fr) | 2009-03-26 |
WO2009038659A3 true WO2009038659A3 (fr) | 2009-09-03 |
Family
ID=40468678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/010608 WO2009038659A2 (fr) | 2007-09-14 | 2008-09-11 | Nanoparticules de silice organiquement modifiées avec des photosensibilisateurs incorporés par covalence pour l'administration de médicaments lors d'une thérapie photodynamique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009038659A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110718966B (zh) * | 2019-10-25 | 2020-12-25 | 云南电网有限责任公司信息中心 | 一种电力设备数据采集及管理方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2464958A (en) * | 2008-10-31 | 2010-05-05 | Univ Muenster Wilhelms | A method for the manufacture of a photosensitising nano-material |
AU2009347929A1 (en) * | 2009-06-12 | 2012-01-19 | Amrita Vishwa Vidyapeetham University | Targeted nano-photomedicines for photodynamic therapy of cancer |
FR2956109B1 (fr) * | 2010-02-11 | 2012-04-20 | Commissariat Energie Atomique | Procede de preparation par voie stober de particules de silice contenant un derive de phtalocyanine, lesdites particules et leurs utilisations. |
US8609837B2 (en) | 2010-07-06 | 2013-12-17 | Health Research, Inc. | Metallation enhancements in tumor-imaging and PDT therapy |
EP2484388A1 (fr) * | 2011-02-05 | 2012-08-08 | MaRVis Technologies GmbH | Dispositif médical implantable ou insérable détectable par IRM doté d'un revêtement comportant des ions paramagnétiques et son procédé de préparation |
CN103827126B (zh) * | 2011-11-18 | 2017-05-17 | 株式会社艾迪科 | 新型化合物和担载该新型化合物的担载体 |
EP2692365A1 (fr) | 2012-08-03 | 2014-02-05 | MaRVis Medical GmbH | Dispositif médical implantable ou insérable détectable par IRM doté dýun revêtement comportant des ions paramagnétiques et son procédé de préparation |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
US9119875B2 (en) | 2013-03-14 | 2015-09-01 | International Business Machines Corporation | Matrix incorporated fluorescent porous and non-porous silica particles for medical imaging |
PT107125B (pt) * | 2013-08-23 | 2019-02-13 | Inst Superior Tecnico | Nanossistema multifuncional superparamagnético como agente de contraste para imagem por ressonância magnética e seu método de produção |
WO2016094991A1 (fr) * | 2014-12-16 | 2016-06-23 | Universidade Estadual De Campinas - Unicamp | Procédé d'obtention de nanoparticules de silice pégylées transporteuses d'agences pharmaceutiques hydrophobes, nanoparticules ainsi obtenues et leurs utilisations |
CN113546042A (zh) * | 2021-07-22 | 2021-10-26 | 中国药科大学 | 一种基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用 |
CN115364211B (zh) * | 2022-08-02 | 2023-12-22 | 北京大学 | 超小酞菁共轭介孔二氧化硅纳米粒子及其作为声敏剂的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20030157021A1 (en) * | 1995-02-02 | 2003-08-21 | Jo Klaveness | Light imaging contrast agents |
US20040180096A1 (en) * | 2003-01-24 | 2004-09-16 | Paras Prasad | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
-
2008
- 2008-09-11 WO PCT/US2008/010608 patent/WO2009038659A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20030157021A1 (en) * | 1995-02-02 | 2003-08-21 | Jo Klaveness | Light imaging contrast agents |
US20040180096A1 (en) * | 2003-01-24 | 2004-09-16 | Paras Prasad | Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110718966B (zh) * | 2019-10-25 | 2020-12-25 | 云南电网有限责任公司信息中心 | 一种电力设备数据采集及管理方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2009038659A2 (fr) | 2009-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009038659A3 (fr) | Nanoparticules de silice organiquement modifiées avec des photosensibilisateurs incorporés par covalence pour l'administration de médicaments lors d'une thérapie photodynamique | |
Chen et al. | Gadolinium‐encapsulated graphene carbon nanotheranostics for imaging‐guided photodynamic therapy | |
Li et al. | Photosensitized singlet oxygen generation and detection: Recent advances and future perspectives in cancer photodynamic therapy | |
Owens et al. | Tissue-specific near-infrared fluorescence imaging | |
Guan et al. | Photodynamic therapy based on nanoscale metal–organic frameworks: from material design to cancer nanotherapeutics | |
Krajczewski et al. | Role of various nanoparticles in photodynamic therapy and detection methods of singlet oxygen | |
Ding et al. | Zinc (II) metalated porphyrins as photothermogenic photosensitizers for cancer photodynamic/photothermal synergistic therapy | |
Li et al. | Sequential protein-responsive nanophotosensitizer complex for enhancing tumor-specific therapy | |
Wang et al. | Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics | |
Ishii | Functional singlet oxygen generators based on phthalocyanines | |
Ethirajan et al. | The role of porphyrin chemistry in tumor imaging and photodynamic therapy | |
Park et al. | Theranostic probe based on lanthanide‐doped nanoparticles for simultaneous in vivo dual‐modal imaging and photodynamic therapy | |
EP2440247B1 (fr) | Nano-photomédicaments ciblés destinés au traitement photodynamique du cancer | |
EP2437653B1 (fr) | Nanoparticules paa permettant d'améliorer l'imagerie tumorale | |
Sandland et al. | Porphyrins and related macrocycles: Combining photosensitization with radio-or optical-imaging for next generation theranostic agents | |
Yao et al. | Boron‐Fluorine Photosensitizers for Photodynamic Therapy | |
Bloyet et al. | Photosensitizer encryption with aggregation enhanced singlet oxygen production | |
Xiong et al. | Photo-controllable biochemistry: Exploiting the photocages in phototherapeutic window | |
Liu et al. | Porphyrin‐Based Nanoparticles: A Promising Phototherapy Platform | |
Boscencu et al. | Porphyrin macrocycles: General properties and theranostic potential | |
Fabris et al. | Tumour-localizing and-photosensitising properties of meso-tetra (4-nido-carboranylphenyl) porphyrin (H2TCP) | |
Xie et al. | Recent Advances in Tetrakis (4‐Carboxyphenyl) Porphyrin‐Based Nanocomposites for Tumor Therapy | |
Gyulkhandanyan et al. | Binding of cationic porphyrins and metalloporphyrins to the human transferrin for photodynamic therapy of tumors | |
Dumoulin | Design and conception of photosensitisers | |
Bechet et al. | Innovations of photodynamic therapy for brain tumors: Potential of multifunctional nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08832507 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08832507 Country of ref document: EP Kind code of ref document: A2 |